Abstract |
Strontium-89 (Sr-89) is a pure emitter with maximum beta energy of 1.46 MeV, average beta energy of 0.58 MeV, and a physical half-life of 50.5 days. It is rapidly taken up by bone and preferentially retained at the sites of osseous metastases. Its biological half-life is >50 days at the metastatic sites, but about 14 days only in the normal bone. The dose of its absorption in the tumor-bearing bone ranges from 21 +/- 4 to 231 +/- 56 cGy/MBq, 2-25 times higher than in the normal bone. Strontium-89 therapy is an effective palliative treatment of bone metastases from prostate cancer, with analgesic effectiveness in 80%.
|
Authors | Wei-wei Zhao, Peng Xie, Hou-fu Deng |
Journal | Zhonghua nan ke xue = National journal of andrology
(Zhonghua Nan Ke Xue)
Vol. 16
Issue 3
Pg. 269-72
(Mar 2010)
ISSN: 1009-3591 [Print] China |
PMID | 20369560
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
|
Topics |
- Bone Neoplasms
(radiotherapy, secondary)
- Humans
- Male
- Neoplasm Metastasis
- Prostatic Neoplasms
(pathology, radiotherapy)
- Strontium Radioisotopes
(therapeutic use)
|